Current Report Filing (8-k)
January 06 2017 - 8:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 6, 2017
ENANTA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35839
|
|
04-3205099
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
500 Arsenal Street, Watertown, Massachusetts 02472
(Address of principal executive offices and zip code)
(617) 607-0800
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
❑
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
❑
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
❑
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
❑
|
Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
On January 6, 2017, Enanta Pharmaceuticals, Inc. provided via press release highlights of its business overview and update on its research and development
programs. A copy of Enantas press release is hereby furnished to the Commission as Exhibit 99.1.
Item 9.01 Financial Statements and
Exhibits.
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release of Enanta Pharmaceuticals, Inc. dated January 6, 2017, announcing highlights of business overview and update on its research and development programs to be presented at the 35
th
Annual J.P. Morgan Healthcare Conference.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
Date: January 6, 2017
|
|
ENANTA PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
/s/ Paul J. Mellett
|
|
|
|
|
Paul J. Mellett
|
|
|
|
|
Senior Vice President, Finance and Administration and Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release of Enanta Pharmaceuticals, Inc., dated January 6, 2017, announcing highlights of business overview and update on its research and development programs to be presented at the 35
th
Annual J.P. Morgan Healthcare Conference.
|
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024